NEW YORK (Reuters Health) - From 1985 to 2007, the CD4+ cell counts seen at diagnosis in HIV-infected patients in the US have fallen, suggesting that the virus may be adapting to the host and becoming more virulent, according to a report in Clinical Infectious Diseases.

These findings agree with those of other researchers, who have reported that patients starting treatment for HIV infection in recent years may have lower CD4+ cell counts at diagnosis and require antiretroviral therapy earlier in the course of disease, Dr. Nancy Crum-Cianflone, from the Naval Medical Center, San Diego, California, and colleagues report.

The study results stem from an analysis of data for 2174 patients who tested positive for HIV antibodies and were enrolled in the TriService AIDS Clinical Consortium HIV Natural History Study. None of the subjects had received antiretroviral treatment and had their CD4+ counts measured within 6 months of their HIV diagnosis. CD4+ cells are immune cells that are used to assess the severity of the infection. As HIV infection progresses, CD4+ cell counts decrease.

The average initial CD4+ cell counts during the periods 1985-1990, 1991-1995, 1996-2001, and 2002-2007 were 632, 553, 493, and 514 cells per microliter, respectively. During the same periods, the percentage of subjects with initial CD4+ cell counts below 350 cells per microliter were 12 percent, 21 percent, 26 percent, and 25 percent.

The reduction in initial CD4+ cell counts was similar in African American and in white patients, the report indicates. Similar trends were also noted for the CD4+ cell count percentage and the total count of lymphocytes, a type of white blood cell involved in the immune response.

In an accompanying editorial, Dr. Maria Dorrucci, from Istituto Superiore di Sanita, Rome, and Dr. Andrew Phillips, from University College Medical School, London, comment that while some studies, such as the current one, have suggested that HIV virulence is increasing, others have found that it is either stable or decreasing.

This, they note, may relate to how virulence is assessed, adding that "it is unclear whether simple immunological or virological proxies for virulence can be expected to adequately capture the whole complexity of HIV virulence" and the susceptibility of the patient to HIV infection.

SOURCE: Clinical Infectious Diseases, May 2009.

• More News on AIDS
• More News on AIDS Medicines

Related MedlinePlus Pages:

• AIDS
• AIDS Medicines